DGAP-News: Biotest AG / Key word(s): Miscellaneous
24.01.2018 / 07:00
The issuer is solely responsible for the content of this announcement.
Biotest AG opens second plasma collection centre in Czech Republic
– 19 plasma collection centres in Europe to ensure long-term plasma supply
Dreieich, 24 January 2018. Biotest received an operating permit for its second plasma collection centre in Czech Republic from the country’s national public health authority SUKL. The centre is located in Břeclav the south-eastern part of the country. At the time of the acquisition of Cara Plasma s.r.o. in July 2017 the Břeclav was in the build-out process. As planned, the plasmapheresis centre is with the permission fully operational.
With the second plasma collection centre in Břeclav, Biotest achieved further milestones for a better self-supply of plasma. With our increased plasma production we can also insure, that our patients can be supplied with life-saving medications out of plasma, stated Dr Martin Reinecke, Senior Vice President Global Plasma Alliances and Protein Supply of Biotest AG.
The collected plasma is processed only by Biotest AG at Dreieich, Germany. Regular audits in Czech Republic ensure that the strict legal and internal quality requirements are met.
About human blood plasma
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com
Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201
24.01.2018 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Phone:||0 61 03 – 8 01-0|
|Fax:||0 61 03 – 8 01-150|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange|
|End of News||DGAP News Service|